SAB4700240
Monoclonal Anti-CD52 antibody produced in mouse
clone HI186, purified immunoglobulin, buffered aqueous solution
Sinônimo(s):
Anti-CAMPATH-1
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352203
NACRES:
NA.41
clone:
HI186, monoclonal
application:
FACS
reatividade de espécies:
human
técnica(s):
flow cytometry: suitable
citations:
1
Produtos recomendados
fonte biológica
mouse
Nível de qualidade
conjugado
unconjugated
forma do anticorpo
purified immunoglobulin
tipo de produto de anticorpo
primary antibodies
clone
HI186, monoclonal
Formulário
buffered aqueous solution
reatividade de espécies
human
concentração
1 mg/mL
técnica(s)
flow cytometry: suitable
Isotipo
IgG2b
nº de adesão NCBI
nº de adesão UniProt
Condições de expedição
wet ice
temperatura de armazenamento
2-8°C
modificação pós-traducional do alvo
unmodified
Informações sobre genes
human ... CD52(1043)
Descrição geral
The antibody HI186 reacts with CD52 (CAMPATH-1), a 21-28 kDa glycoprotein containing a large N-linked carbohydrate moiety; mature CD52 molecule is actually much smaller (approx. 8-9 kDa). CD52 is expressed at high levels on lymphocytes, monocytes/macrophages and in male reproductive tract.
Imunogênio
Human tonsil
Aplicação
The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 2 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Características e benefícios
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
forma física
Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.
Exoneração de responsabilidade
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Não está encontrando o produto certo?
Experimente o nosso Ferramenta de seleção de produtos.
Código de classe de armazenamento
10 - Combustible liquids
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Escolha uma das versões mais recentes:
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
T Nikolic et al.
Genes and immunity, 18(3), 176-183 (2017-08-11)
Tolerogenic dendritic cells (tolDCs) are assessed as immunomodulatory adjuvants to regulate autoimmunity. The underlying gene expression endorsing their regulatory features remains ill-defined. Using deep mRNA sequencing, we compared transcriptomes of 1,25-dihydroxyvitaminD
Sarah K Tasian et al.
Blood, 129(17), 2395-2407 (2017-03-02)
We and others previously reported potent antileukemia efficacy of CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical human acute myeloid leukemia (AML) models at the cost of severe hematologic toxicity. This observation raises concern for potential myeloablation in patients
Gaetano Lucisano et al.
Transplant international : official journal of the European Society for Organ Transplantation, 32(9), 949-959 (2019-04-14)
There are conflicting data about the role of transplant nephrectomy and immunosuppression withdrawal on the development of allosensitization and the impact on re-transplantation. We divided 109 first graft recipients into two groups according to whether they underwent nephrectomy (NX+, n = 61)
Jianhui Liu et al.
Biological & pharmaceutical bulletin, 41(9), 1423-1429 (2018-06-15)
Recent studies suggested that excessive T helper (Th)1/17 cells concomitant with regulatory T cell deficiency might play important roles in Crohn's disease. Anti-cluster of differentiation 52 (CD52) monoclonal antibody (mAb), which aims on CD52 antigen on mature immunocytes, has both
Carlos Cuesta-Mateos et al.
Biomarker research, 8, 54-54 (2020-10-29)
T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica